Elewski 2016

Methods	Randomised, placebo‐controlled, double‐blind trial date: January 2014 to April 2016 Location: worldwide
Participants	Total sample size: 217 Inclusion criteria Adults with clinical diagnosis of chronic plaque psoriasis (with a disease duration of ≥ 6 months) and ≥ 1 fingernail with nail psoriasis BSA ≥ 10% and a target fingernail mNAPSI ≥ 8 at Week 0, OR BSA ≥ 5%, a target fingernail Nail Psoriasis Severity index (NAPSI) ≥ 8 and a total mNAPSI score of ≥ 20 at Week 0 Nail Psoriasis Physical Functioning Severity score of > 3, OR a Nail Psoriasis Pain score of > 3 PGA of fingernail psoriasis and a PGA of skin psoriasis of ≥ moderate Must have discontinued use of all systemic therapies for the treatment of psoriasis, or systemic therapies known to improve psoriasis for ≥ 4 weeks prior to Week 0, ustekinumab must have been discontinued ≥ 12 weeks prior to Week 0 Target fingernail must have mNAPSI score of ≥ 8 Exclusion Criteria Prior adalimumab therapy Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with evaluation of skin or fingernail psoriasis Recent infection requiring treatment Significant medical events or conditions that may put patients at risk for participation, including recent history of drug or alcohol abuse Women who are pregnant or breast‐feeding or considering becoming pregnant during the study History of cancer, except successfully treated skin cancer
Interventions	Intervention Adalimumab, SC, 40 mg, eow for 25 weeks starting 1 week after initial loading dose of 80 mg Control intervention Placebo
Outcomes	At week 12 mNAPSI 75, PGA of fingernails of clear or minimal PASI 75/90/100 for participants with baseline PASI at 5
Notes	NCT02016482 Enrollment: 217 Study start date: January 2014 Study completion date: April 2016 Abstract Journal of the European Academy of Dermatology and Venereology 2016, 30:65 No original paper published. We emailed the study authors (3 and 12 January 2017) for the protocol and results. Abbvie response: "As this data has not been published in a manuscript at this time I am providing the link below for you to submit a request for this data. Please let me know if you have any further questions". Will be included when published